3 Stocks Pulling The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 115 points (0.7%) at 16,388 as of Friday, Feb. 28, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,987 issues advancing vs. 938 declining with 158 unchanged.

The Health Care sector currently sits down 0.2% versus the S&P 500, which is up 0.6%. On the negative front, top decliners within the sector include Medivation ( MDVN), down 13.5%, Questcor Pharmaceuticals ( QCOR), down 7.8%, Endo Health Solutions ( ENDP), down 6.6%, Jazz Pharmaceuticals ( JAZZ), down 4.4% and Intercept Pharmaceuticals ( ICPT), down 3.5%. Top gainers within the sector include Fresenius Medical Care AG & Co. KGaA ( FMS), up 3.6%, WellPoint ( WLP), up 2.8%, Grifols ( GRFS), up 2.8%, Amgen ( AMGN), up 2.4% and Teva Pharmaceutical Industries ( TEVA), up 1.9%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Shire ( SHPG) is one of the companies pushing the Health Care sector lower today. As of noon trading, Shire is down $4.20 (-2.5%) to $166.95 on heavy volume. Thus far, 767,703 shares of Shire exchanged hands as compared to its average daily volume of 440,300 shares. The stock has ranged in price between $165.52-$171.24 after having opened the day at $171.03 as compared to the previous trading day's close of $171.15.

Shire plc, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $33.7 billion and is part of the drugs industry. Shares are up 21.1% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts that rate Shire a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Shire Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead